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Background
As the COVID-19 pandemic evolves, more evidence becomes 
available on the nature of this novel disease and how it affects 
individuals in different ways. From the beginning COVID-19 
was thought to be a ‘viral pneumonia’ (1). Gradually, it turns 
out to be a disease that affects many different organs and 
presents with a variety of different symptoms and diseases 
(2). It has been stated that COVID-19 somehow is more of an 
immunological disease than an infectious disease. Recently, 
hypercoagulability, thromboembolic events, and vascular 
characteristics associated with COVID-19 have been highlight-
ed (2). There is increasing evidence that the viral infection in 
certain patients causes a severe immunological reaction which 
actually is responsible for the severe mortality and morbidity 
seen with COVID-19 (1). 
Immunological phenomena of COVID-19
The immune response of patients affected by COVID-19 ap-
pears to be the main cause of organ damage, including severe 
lung tissue damage (1). The primary immune response leads 
to viral clearance in the vast majority of those getting ill with 
COVID-19. A minority of patients develops a severe secondary 
immune response. The severe reaction of the immune system 
probably occurs as this novel coronavirus is unknown to the 
human body (3). The immune system reacts by producing 
high levels of cytokines including interleukin 6, interleukin 1, 
anti-tumour necrosis factor, and macrophages. This cytokine 
storm and systemic hyperinflammatory response is associated 
with adverse outcome leading to severe inflammatory-induced 
lung injury and other complications including pneumonitis, 
acute respiratory distress syndrome, respiratory failure, shock, 
organ failure, and death (1,4). It is still unclear which compo-
nent of the cytokine storm causes most damage (5).  
Aside of lung injury, major vascular complications have been 
described with COVID-19. This includes patients with severe 
stroke, cardiac problems, mesenterial ischaemia and dark 
colouring of the toes (2). Patients with COVID-19 are at high 
risk of developing thromboembolic events, both in major 
blood vessels, but micro thromboembolism also occurs in 
small blood vessels. These vascular complications can occur 
in all organs of the body, and appear to be the result of a 
reaction of the endothelial cell function of blood vessels. En-
dothelial cell infection, endotheliitis and thromboembolism 
are pathological findings in these patients (2). Recently, it has 
become clear that pulmonary thromboembolism also plays a 
role in respiratory failure. Blood vessels especially in the lower 
regions of the lungs are affected. Recognition of the frequent 
incidence of thromboembolic events with COVID-19 means 
that patients with moderate–severe disease now are treated 
with double dose low molecular weight heparin.
Recently, another immunological phenomenon associated 
with COVID-19 has been reported in children in different 
countries (6). This concerns children presenting with Kawasa-
ki-like symptoms, and has been called the ‘paediatric inflam-
matory multisystem syndrome’. These children get severely 
ill several weeks after infection with COVID-19, and even 
mortality has been reported (7). The classic Kawasaki disease 
we know is primarily a vasculitis of medium-sized arteries. 
Kawasaki disease typically occurs in children below 5 years of 
age. Children with Kawasaki disease present with fever, erythe-
ma of the lips and oral mucosa, rash, and changes in the ex-
tremities including erythema of the palms and soles, bilateral 
non-exudative conjunctivitis and cervical lymphadenopathy 
(8). These features normally develop after a short course of 
respiratory or gastrointestinal symptoms (8). The aetiology of 
classic Kawasaki disease is unknown (9). It is thought to be 
caused by an overreaction of the immune system following a 
mild infection (8). Earlier an association of Kawasaki disease 
with another coronavirus, the Coronavirus NL63, was suggest-
ed, but could not be confirmed (10). Children affected by the 
COVID-19-associated paediatric inflammatory multisystem 
syndrome are often older (mean age 7.5 years) than those 
affected with classic Kawasaki disease (< 5 years of age) (6, 7). 
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and hyperinflammation (1,4,5,). These immunosuppressive 
drugs include treatment with low-dose corticosteroids, inter-
leukin-1 receptor antagonists, interleukin-6 receptor antago-
nists, mammalian target of rapamycin inhibitors, IFN-γ, intra-
venous immunoglobulin and anti-tumour necrosis factor (1, 4, 
15).  These treatments should be balanced in order to reduce 
the hyperinflammation, but the immune system should still 
be able to respond to the infection and bacterial infections (3)
dermatological patients on immunomodulating treat-
ment
Whether patients on immunomodulating treatment for der-
matological, gastrointestinal and rheumatological diseases 
are at increased risk for adverse outcomes when infected by 
COVID-19 is still unclear (16–18). There is no evidence that 
psoriasis patients treated with biologics have a high risk of 
being infected, or a higher risk of a severe course of the disease 
(19). It has been pointed out that evidence is lacking to stop 
treatment with biologicals as a preventive measure (19, 20). 
Hence, most do not advice to discontinue medication. Of 
course, this must be considered on an individual basis, and 
like the rest of the population, elderly patients with pulmonary 
and cardiovascular comorbidities are at increased risk (17, 19). 
Careful consideration of whether the skin disease justifies 
immunosuppressive treatment should always be considered, 
especially when starting new patients on immunomodulating 
drugs (21). Furthermore, age, comorbidity, and obesity should 
be taken into consideration when advising these patients.
In patients with active infectious disease, discontinuation of 
biologics has been the rule, and this has also been advised 
for COVID-19 infection (16). A report from Italy describes 
continuing biological treatment in asymptomatic patients 
or patients with mild symptoms without fever and without 
contact to COVID-19 patients (22). Treatment was discontin-
ued in patients with moderate or severe respiratory symptoms 
(fever, cough and/or difficulty breathing) and without COV-
ID-19 contacts. In this group treatment was restarted when 
complete remission of symptoms was reached and after at least 
72 h without fever. Treatment was discontinued in patients 
with mild respiratory problems and contact to COVID-19 
confirmed cases until the patient had a laboratory-confirmed 
negative test for COVID-19. In patients with moderate to se-
vere respiratory symptoms and contact to COVID-19 patients 
or clinical/radio logical COVID-19, treatment was interrupted, 
and patients were admitted to a COVID-19 hospital (22). More 
data is urgently needed to identify specific patients at high-
risk of an adverse outcome. The international league of der-
matological societies has launched an app titled ‘PSOprotect’ 
to register how psoriasis patients taking immunomodulating 
Occurrence of this COVID-19 associated paediatric inflam-
matory multisystem syndrome is worrisome, especially as it 
was previously thought that children only get mild symptoms 
when infected with COVID-19. This might be true for the ma-
jority, but Kawasaki-like symptoms occurring after the initial 
infection may be the exception to the rule. Classic Kawasaki 
disease is treated with immunoglobulins to reduce the risk of 
aneurysms of the coronary arteries (8). Whether patients with 
the paediatric inflammatory multisystem syndrome also are 
at risk of developing coronary artery aneurysms remains to be 
determined. Immunoglobulin treatment is beneficial in classic 
Kawasaki disease, but we do not know whether this should 
also be applied in children with the COVID-19 associated 
paediatric inflammatory multisystem syndrome.
Immunological phenomena and Immunosuppression
Considering these immunological phenomena of COVID-19, 
the question arises how we should estimate the risk of a severe 
course of COVID-19 in patients on immunomodulating and 
immunosuppressive medication (11,12). 
It was assumed that patients with a suppressed immune 
system would have a higher risk of an adverse outcome with 
COVID-19 because they are at increased risk when affected 
by common viral infections with adenovirus, rhinovirus, 
norovirus, and influenza (11). Based on this assumption, im-
munosuppressed patients were advised to be extremely careful 
regarding COVID-19 (12, 13). 
Many patients on immunomodulating and immunosup-
pressive agents have avoided any risk of getting infected 
with COVID-19. These patients have isolated themselves in 
their homes and taken other preventive measures (12). Now, 
as the pandemic continues and countries are beginning to 
lift lockdown measures, it is important to know how these 
patients should act. 
Patients on immunomodulating and immunosuppressive 
medication include patients with dermatological, gastro-
intestinal, and rheumatological diseases but also bone marrow 
and solid organ transplant recipients. Alongside these groups 
there are other groups with weak immune systems, and lower 
immune capacities to fight infections and cancer. This group 
of immunocompromised includes those with an inherited 
immunodeficiency, people with HIV, patients with bad nu-
tritional status and cancer patients (especially those in active 
chemotherapy). Also, their risk when infected with COVID-19 
has been questioned and remains to be determined.
Interestingly, immunosuppressive drugs are part of the treat-
ment strategies currently tested for COVID-19 (14). These 
immunosuppressive drugs aim at reducing this cytokine storm 
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medication are affected by COVID-19 infections (PSO-Pro-
tect)(23). Furthermore, an online registry for patients with 
atopic dermatitis on immunomodulating medication, the 
SECURE-AD registry, has been launched (SECURE-AD) (24). 
Similar registries exist for rheumatological (Rheum-covid) 
and gastrointestinal patients (Covidibd) (25, 26). The NICE 
Institute in the UK has prepared guidelines for dermatological 
patients on immunomodulating medication which are in 
line with recommendations from the British Dermatological 
Society (NICE) (27). They advise to avoid unnecessary hospital 
visits, to carefully consider when starting new patients on im-
munomodulating medication, and to advise on an individual 
basis whether patients should continue treatment (NICE) (27). 
immunosuppressed organ transplant recipients
Early reports from China and Italy suggested that immunosup-
pressed organ transplant recipients did not have a more severe 
course of COVID-19 infection than the general population (11, 
13, 28–32). Later reports have confirmed these early findings 
and currently it is assumed that high age and presence of 
cardio pulmonary co-morbidities, just as in the general pop-
ulation increase the risk of a severe outcome (33). Whether 
immunosuppressed organ transplant recipients more often 
experience a mild form of the disease due to lack of an extreme 
immune response against the virus remains to be determined. 
Also, evidence lacks whether immunosuppressed treatment 
should be reduced when an active COVID-19 infection occurs.
Risk of infection
A study from Italy including 160 kidney transplant recipients 
who were either children or young adults, did not report any 
occurrence of COVID-19. Based on this, they advised not to 
change chronic immunosuppression in this group (34). In 
addition, a case series from Italy showed that paediatric liver 
transplant recipients, despite being immunosuppressed, were 
not at increased risk of severe pulmonary disease compared 
with the general population (11). A Chinese study on 87 heart 
transplant recipients from the Hubei province reported that 4 
patients developed upper airway symptoms, but none of them 
was tested positive (32). 
Course of disease
Early reports from Italy initially described that no COVID-19 
fatalities had occurred among transplanted patients (11). 
Though, more recent studies reported on 3 long-term liver 
transplant survivors who died due to COVID-19 out of a 
total of 111 long-term transplant survivors (33). Character-
istic for all of them was that they received very low doses of 
immunosuppression as they had been transplanted long ago. 
Furthermore, all 3 were males, older than 65 years, overweight, 
and all had severe co-morbidity with diabetes, hypertension 
and hyperlipidaemia (33). Cases from China on COVID-19 in 
heart, kidney and liver transplant recipients report successful 
recovery (28–32). Reports from Spain and the US agree that 
immunosuppressed transplanted patients do not experience 
a more severe course of the disease (35, 36). A study from 
Spain reports on 33 kidney transplant recipients infected with 
COVID-19: 2 patients of high age (87 and 72 years) died, 1 
patient with chronic graft dysfunction lost a graft, 21 patients 
recovered and were discharged, 2 patients were at the time 
of the report in intensive care unit (ICU) with non-invasive 
ventilation (35). A study from New York reported on 41 renal 
transplant recipients with confirmed or suspected COVID-19 
disease, one third required hospitalization, and at the end of 
the follow-up no mortality had occurred (36). Another report 
describes 12 renal transplant recipients with a severe disease 
course, of which 4 patients recovered and 8 patients died (37).
A hospital in South-eastern Michigan, US, admitted 13 heart 
transplant recipients with COVID-19. Six of these required 
admission at the ICU, and 2 eventually died. All 13 patients 
were black males (38). A Chinese case report describes a re-
nal transplant patient and a bone marrow transplant, both 
Fig. 1. Patients with severe psoriasis on immunomodulating medication.
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infected with COVID-19. Maintenance immunosuppression 
was withdrawn in these two patients, and treatment with 
low-dose cortico steroids was initiated, unfortunately with 
fatal outcome (39). 
An Italian transplant centre reports on two lung transplant 
recipients infected with COVID-19 (40). In both patients 
mycop henolate mofetil was stopped when patients were 
tested positive. In the first patient calcineurin inhibitor ad-
ministration was continued, while in the second patient this 
was stopped. The first patient had a favourable course and 
was discharged, while the second patient died (40).  Two lung 
transplant recipients from a German transplant centre were 
tested positive for COVID-19. One was without symptoms and 
the other only had mild symptoms. Both had a favourable 
course (41).
cancer patients
A Chinese study from 3 hospitals in Wuhan reported on 
28 cancer patients infected with COVID-19 (42). The most 
common type of cancer in this group was lung cancer (25%). 
Serious adverse events in these patients were very common, 
and mortality was high (29%). Especially patients who had 
received active therapy within the last 14 days were at high 
risk for serious adverse events (42). Reviews and guidelines 
regarding care of cancer patients during the COVID-19 pan-
demic have been launched (43). Patients on active treatment 
have increased risk of an unfavourable course of disease (43). 
This means that preventive measures to avoid infection should 
be taken, unnecessary hospital visits should be avoided, and 
cancer treatment should be well-planned. It is also important 
to acknowledge that postponed or cancelled cancer treatment 
affects survival in these patients. A randomised trial specifi-
cally looking at treatment of COVID-19 in cancer patients is 
currently being performed (43).   
discussion
Risk assessment related to COVID-19 appears to be very 
complicated. We have seen healthy people between 15 and 
35 years old who died of COVID-19, while a 102-year-old 
person recovered.
From start we feared that patients on immunosuppression were 
at higher risk of having a severe courses of COVID-19 (11). 
As the pandemic evolves, our understanding of the disease 
increases and data on presentation and course of the disease 
in different patient populations become available. More data 
and evidence is needed, as present knowledge is scarce and 
often based on small case studies.  
At present, it is not possible to draw firm conclusions on whether 
immunosuppressed patients have a higher risk of adverse 
outcome when infected by COVID-19. Studies on immuno-
suppressed transplanted patients suggest that major risk factors 
for adverse outcome are age and cardiovascular comorbidity 
rather than immunosuppression (33). Available reports suggest 
an increased risk for cancer patients in active therapy (42, 43). 
Whether immunosuppression helps to prevent a cytokine 
storm in immunosuppressed patients remains to be elucidated 
(14). We also do not know whether immunosuppressive med-
ication can play a role in the treatment of COVID-19 (1, 14). 
More research is necessary to characterize the full spectrum 
of clinical illnesses, transmission efficiency, and the duration 
of viral shedding for immunocompromised patients with 
COVID-19 (44, 45). 
Currently, there is no clear evidence to support an interrup-
tion of immunomodulating medication in our dermatological 
patients, but more epidemiological data is necessary to assess 
the risk of adverse outcomes with COVID-19.  
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